Biosimilar SB15 versus reference aflibercept in neovascular age-related macular degeneration 1-year and switching results of a phase 3 clinical trial /
To evaluate efficacy, safety, pharmacokinetics (PK) and immunogenicity of SB15 versus reference aflibercept (AFL), and switching from AFL to SB15 in neovascular age-related macular degeneration (nAMD).Prospective, double-masked, randomised, phase 3 trial.Participants with nAMD were randomised 1:1 to...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2023
|
| Sorozat: | BMJ OPEN OPHTHALMOLOGY
8 No. 1 |
| Tárgyszavak: | |
| doi: | 10.1136/bmjophth-2023-001561 |
| mtmt: | 34477400 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/30469 |